Sativex for MS spasticity was effective but unlikely to be cost-effective in the UK | Research

The takeaway

Economic modeling found Sativex cost approximately 49,300 pounds per quality-adjusted life year gained, exceeding the UK's 30,000 pound willingness-to-pay threshold for cost-effectiveness.

Read this if you want to understand why effective medical cannabis treatments may not be available through public health systems.

49,300 pounds per QALY vs 30,000-pound threshold

What the researchers found

Using a Markov model to project costs and quality-of-life benefits over 5 years, researchers estimated that adding Sativex to standard spasticity treatment cost an additional 7,600 pounds and gained 0.15 QALYs per patient. This yielded an incremental cost-effectiveness ratio (ICER) of 49,300 pounds per QALY.

At the UK's standard willingness-to-pay threshold of 30,000 pounds per QALY, Sativex was unlikely to be considered cost-effective. The results were most sensitive to Sativex price, daily dose, and the difference in quality of life between responders and non-responders.

The authors acknowledged this was "unfortunate" since Sativex appeared to benefit some patients, but the cost-per-benefit ratio did not meet standard economic thresholds.

Why it matters

This analysis revealed the tension between clinical efficacy and economic viability. A treatment can work and still not be funded if the cost per unit of benefit exceeds what healthcare systems are willing to pay.

The numbers in context

Incremental cost: 7,600 pounds per patient over 5 years. QALY gain: 0.15 per patient. ICER: 49,300 pounds per QALY. UK WTP threshold: 30,000 pounds. Sativex unlikely cost-effective at current pricing.

How the study worked

Cost-effectiveness analysis using a Markov model. Compared Sativex plus oral anti-spasticity medicines versus current standard treatment over 5 years. Primary outcome: ICER in cost per QALY. Sensitivity analyses explored uncertainty. UK healthcare perspective with 2009 cost data.

What this study cannot tell us

Modeling depends on assumptions about treatment duration, response rates, and quality-of-life estimates. Five-year time horizon may not capture all relevant costs and benefits. UK cost structure may not apply to other countries.

How to read the evidence

Rigorous cost-effectiveness analysis with sensitivity testing. Standard health economic methodology. Results depend on input assumptions.

When this study was published

Published in 2012. Sativex pricing and access policies have evolved since, with ongoing cost-effectiveness debates in multiple countries.

The bigger picture

This economic analysis influenced prescribing access in the UK, where NICE guidelines consider cost-effectiveness. Patients who could benefit clinically may not have had access due to economic constraints, creating an ethical dilemma familiar in pharmaceutical economics.

Questions still open

Would a lower Sativex price make it cost-effective? Could a responder enrichment strategy improve the ICER by avoiding treatment costs in non-responders? Should rare but meaningful quality-of-life improvements be valued differently?

Common questions

Why is Sativex not widely available through the NHS?

This economic analysis showed Sativex costs about 49,300 pounds per quality-adjusted life year, well above the 30,000-pound threshold the NHS typically uses for funding decisions. Despite clinical benefit for some patients, the cost-per-benefit ratio exceeded standard willingness-to-pay levels.

Does "not cost-effective" mean it does not work?

No. Sativex was shown to reduce spasticity in clinical trials. "Not cost-effective" means the clinical benefit, while real, is not large enough relative to the drug's cost to justify public healthcare funding at current prices under standard economic criteria.

Read the original research

Cost effectiveness of oromucosal cannabis-based medicine (Sativex®) for spasticity in multiple sclerosis.

PharmacoEconomics, 30(12), 1157-71

View on PubMed ↗Publisher’s paper ↗

Citation

Lu, Lanting; Pearce, Hilary; Roome, Chris; Shearer, James; Lang, Iain A; Stein, Ken. (2012). Cost effectiveness of oromucosal cannabis-based medicine (Sativex®) for spasticity in multiple sclerosis.. PharmacoEconomics, 30(12), 1157-71. https://doi.org/10.2165/11598470-000000000-00000